144 related articles for article (PubMed ID: 34268520)
1. Pre-vaccination and early B cell signatures predict antibody response to SARS-CoV-2 mRNA vaccine.
Kardava L; Rachmaninoff N; Lau WW; Buckner CM; Trihemasava K; de Assis FL; Wang W; Zhang X; Wang Y; Chiang CI; Narpala S; Reger R; McCormack GE; Seamon CA; Childs RW; Suffredini AF; Strich JR; Chertow DS; Davey RT; Sneller MC; O'Connell S; Li Y; McDermott A; Chun TW; Fauci AS; Tsang JS; Moir S
medRxiv; 2021 Jul; ():. PubMed ID: 34268520
[TBL] [Abstract][Full Text] [Related]
2. Early human B cell signatures of the primary antibody response to mRNA vaccination.
Kardava L; Rachmaninoff N; Lau WW; Buckner CM; Trihemasava K; Blazkova J; Lopes de Assis F; Wang W; Zhang X; Wang Y; Chiang CI; Narpala S; McCormack GE; Liu C; Seamon CA; Sneller MC; O'Connell S; Li Y; McDermott AB; Chun TW; Fauci AS; Tsang JS; Moir S
Proc Natl Acad Sci U S A; 2022 Jul; 119(28):e2204607119. PubMed ID: 35759653
[TBL] [Abstract][Full Text] [Related]
3. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
4. mRNA-based SARS-CoV-2 Comirnaty vaccine elicits weak and short specific memory B cell response in individuals with no previous infection.
Casado JL; Vizcarra P; Martín-Hondarza A; Gómez-Maldonado S; Muedra-Sánchez M; Del Pino J; Mirabella IG; Martín-Colmenarejo S; Haemmerle J; Fernández-Escribano M; Vallejo A
Front Immunol; 2023; 14():1127379. PubMed ID: 37457694
[TBL] [Abstract][Full Text] [Related]
5. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination.
Goel RR; Apostolidis SA; Painter MM; Mathew D; Pattekar A; Kuthuru O; Gouma S; Hicks P; Meng W; Rosenfeld AM; Dysinger S; Lundgreen KA; Kuri-Cervantes L; Adamski S; Hicks A; Korte S; Oldridge DA; Baxter AE; Giles JR; Weirick ME; McAllister CM; Dougherty J; Long S; D'Andrea K; Hamilton JT; Betts MR; Luning Prak ET; Bates P; Hensley SE; Greenplate AR; Wherry EJ
Sci Immunol; 2021 Apr; 6(58):. PubMed ID: 33858945
[TBL] [Abstract][Full Text] [Related]
6. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses.
Turner JS; O'Halloran JA; Kalaidina E; Kim W; Schmitz AJ; Zhou JQ; Lei T; Thapa M; Chen RE; Case JB; Amanat F; Rauseo AM; Haile A; Xie X; Klebert MK; Suessen T; Middleton WD; Shi PY; Krammer F; Teefey SA; Diamond MS; Presti RM; Ellebedy AH
Nature; 2021 Aug; 596(7870):109-113. PubMed ID: 34182569
[TBL] [Abstract][Full Text] [Related]
8. mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals.
Longet S; Hargreaves A; Healy S; Brown R; Hornsby HR; Meardon N; Tipton T; Barnes E; Dunachie S; Duncan CJA; Klenerman P; Richter A; Turtle L; de Silva TI; Carroll MW
Front Immunol; 2022; 13():953949. PubMed ID: 36159846
[TBL] [Abstract][Full Text] [Related]
9. The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.
Fiorino F; Ciabattini A; Sicuranza A; Pastore G; Santoni A; Simoncelli M; Polvere J; Galimberti S; Baratè C; Sammartano V; Montagnani F; Bocchia M; Medaglini D
Front Immunol; 2022; 13():1017863. PubMed ID: 36248803
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal Analysis Reveals Distinct Antibody and Memory B Cell Responses in SARS-CoV2 Naïve and Recovered Individuals Following mRNA Vaccination.
Goel RR; Apostolidis SA; Painter MM; Mathew D; Pattekar A; Kuthuru O; Gouma S; Kuri-Cervantes L; Meng W; Adamski S; Baxter AE; Giles JR; Weirick ME; McAllister CM; Hicks A; Korte S; Dougherty J; Long S; D'Andrea K; Hamilton JT; Prak ETL; Betts MR; Bates P; Hensley SE; Greenplate AR; Wherry EJ
medRxiv; 2021 Mar; ():. PubMed ID: 33688691
[TBL] [Abstract][Full Text] [Related]
11. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers.
Moncunill G; Aguilar R; Ribes M; Ortega N; Rubio R; Salmerón G; Molina MJ; Vidal M; Barrios D; Mitchell RA; Jiménez A; Castellana C; Hernández-Luis P; Rodó P; Méndez S; Llupià A; Puyol L; Rodrigo Melero N; Carolis C; Mayor A; Izquierdo L; Varela P; Trilla A; Vilella A; Barroso S; Angulo A; Engel P; Tortajada M; García-Basteiro AL; Dobaño C
EBioMedicine; 2022 Jan; 75():103805. PubMed ID: 35032961
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2-Specific Memory B Cell Responses Are Maintained After Recovery from Natural Infection and Postvaccination.
Moore T; Hossain R; Doores KJ; Shankar-Hari M; Fear DJ
Viral Immunol; 2022 Jul; 35(6):425-436. PubMed ID: 35857310
[TBL] [Abstract][Full Text] [Related]
13. A FluoroSpot B assay for the detection of IgA and IgG SARS-CoV-2 spike-specific memory B cells: Optimization and qualification for use in COVID-19 vaccine trials.
Bisceglia H; Barrier J; Ruiz J; Pagnon A
J Immunol Methods; 2023 Apr; 515():113457. PubMed ID: 36914088
[TBL] [Abstract][Full Text] [Related]
14. Trajectory of Spike-Specific B Cells Elicited by Two Doses of BNT162b2 mRNA Vaccine.
Ciabattini A; Pastore G; Lucchesi S; Montesi G; Costagli S; Polvere J; Fiorino F; Pettini E; Lippi A; Ancillotti L; Tumbarello M; Fabbiani M; Montagnani F; Medaglini D
Cells; 2023 Jun; 12(13):. PubMed ID: 37443740
[TBL] [Abstract][Full Text] [Related]
15. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
[TBL] [Abstract][Full Text] [Related]
16. Determinants of Antibody Responses to SARS-CoV-2 Vaccines: Population-Based Longitudinal Study (COVIDENCE UK).
Jolliffe DA; Faustini SE; Holt H; Perdek N; Maltby S; Talaei M; Greenig M; Vivaldi G; Tydeman F; Symons J; Davies GA; Lyons RA; Griffiths CJ; Kee F; Sheikh A; Shaheen SO; Richter AG; Martineau AR
Vaccines (Basel); 2022 Sep; 10(10):. PubMed ID: 36298466
[TBL] [Abstract][Full Text] [Related]
17. Impact of Previous Common Human Coronavirus Exposure on SARS-CoV-2-Specific T-Cell and Memory B-Cell Response after mRNA-Based Vaccination.
Casado JL; Vizcarra P; Martín-Hondarza A; Blasco M; Grandal-Platero M; Haemmerle J; Fernández-Escribano M; Vallejo A
Viruses; 2023 Feb; 15(3):. PubMed ID: 36992336
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
Front Immunol; 2022; 13():846753. PubMed ID: 35309297
[TBL] [Abstract][Full Text] [Related]
19. Response to Severe Acute Respiratory Syndrome Coronavirus 2 Initial Series and Additional Dose Vaccine in Patients With Predominant Antibody Deficiency.
Barmettler S; DiGiacomo DV; Yang NJ; Lam T; Naranbhai V; Dighe AS; Burke KE; Blumenthal KG; Ling M; Hesterberg PE; Saff RR; MacLean J; Ofoman O; Berrios C; St Denis KJ; Lam EC; Gregory D; Iafrate AJ; Poznansky M; Lee H; Balazs A; Pillai S; Farmer JR
J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1622-1634.e4. PubMed ID: 35381395
[TBL] [Abstract][Full Text] [Related]
20. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.
Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K
Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
